Positive list system to restrict drug demand will hurt pharmaceutical sector

The government is implementing its new drug pricing policy, the so-called positive list system, to exclude drugs of low quality from the insurance-covered drug lists, but this will deal blow to small and uncompetitive players, according to a local expert.

In a recent forum, Lim Chin-gyun of Daewoo Securities said that under the current pricing scheme, Korean drug makers will be thrown into a...